Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity

EMBO J. 2021 Mar 1;40(5):e106228. doi: 10.15252/embj.2020106228. Epub 2020 Dec 1.

Abstract

Nucleoprotein (N) is an immunodominant antigen in many enveloped virus infections. While the diagnostic value of anti-N antibodies is clear, their role in immunity is not. This is because while they are non-neutralising, they somehow clear infection by coronavirus, influenza and LCMV in vivo. Here, we show that anti-N immune protection is mediated by the cytosolic Fc receptor and E3 ubiquitin ligase TRIM21. Exploiting LCMV as a model system, we demonstrate that TRIM21 uses anti-N antibodies to target N for cytosolic degradation and generate cytotoxic T cells (CTLs) against N peptide. These CTLs rapidly eliminate N-peptide-displaying cells and drive efficient viral clearance. These results reveal a new mechanism of immune synergy between antibodies and T cells and highlights N as an important vaccine target.

Keywords: TRIM21; antibody; non-neutralising; nucleoprotein; virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / immunology*
  • Immunity, Cellular*
  • Lymphocytic Choriomeningitis / genetics
  • Lymphocytic Choriomeningitis / immunology
  • Lymphocytic choriomeningitis virus / genetics
  • Lymphocytic choriomeningitis virus / immunology*
  • Mice
  • Mice, Knockout
  • Nucleocapsid Proteins / genetics
  • Nucleocapsid Proteins / immunology*
  • Ribonucleoproteins / genetics
  • Ribonucleoproteins / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology

Substances

  • Antibodies, Viral
  • Nucleocapsid Proteins
  • Ribonucleoproteins
  • SS-A antigen
  • Viral Vaccines